Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy

por Malecki, Maciej T., Cao, Dachuang, Liu, Rong, Hardy, Thomas, Bode, Bruce, Bergenstal, Richard M., Bue-Valleskey, Juliana
Publicado 2020

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

por Klaff, Leslie, Cao, Dachuang, Dellva, Mary Anne, Tobian, Janet, Miura, Junnosuke, Dahl, Dominik, Lucas, Jean, Bue‐Valleskey, Juliana
Publicado 2020

Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension

por Bue-Valleskey, Juliana, Klaff, Leslie, Cho, Jang Ik, Dellva, Mary Anne, Schloot, Nanette C., Tobian, Janet, Miura, Junnosuke, Dahl, Dominik
Publicado 2021

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

por Kazda, Christof M., Bue-Valleskey, Juliana M., Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Wullenweber, Paula, Haupt, Axel, Dahl, Dominik
Publicado 2023

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

por Bue-Valleskey, Juliana M., Kazda, Christof M., Ma, Chenchen, Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Haupt, Axel, Frias, Juan P.
Publicado 2023

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, cross...

por Heise, Tim, Linnebjerg, Helle, Coutant, David, LaBell, Elizabeth, Zijlstra, Eric, Kapitza, Christoph, Bue‐Valleskey, Juliana, Zhang, Qianyi, Dellva, Mary Anne, Leohr, Jennifer
Publicado 2020